Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications
about
Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectivesHBV induced HCC: major risk factors from genetic to molecular levelAdvanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-upCombination treatment including targeted therapy for advanced hepatocellular carcinomaEndoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells.Current management of hepatocellular carcinoma.Over-expression of Thrombospondin 4 correlates with loss of miR-142 and contributes to migration and vascular invasion of advanced hepatocellular carcinomaEfficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials.Enhanced tumour cell nuclear targeting in a tumour progression model.mTOR inhibition in management of advanced breast cancer.Ramucirumab for the treatment of gastroesophageal cancers.Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment.Pathways and targets in hepatocellular carcinoma.Targeted therapies in the treatment of advanced hepatocellular carcinomaCritical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.Ramucirumab: first global approval.Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study.Hepatocellular Carcinoma: Current Questions and Future Directions.Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.Analysis of the Mitochondrial 4977 Bp Deletion in Patients with Hepatocellular Carcinoma.Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors
P2860
Q26822664-007CF8B0-4714-4227-B14B-0EBF3A16C839Q26825274-E3FDBA36-B72F-43B3-A80F-2974CF46625DQ26851033-A3E311D6-9CFD-4DAD-952F-5BDE139E5BE6Q28077738-09003220-5A62-45DC-B6D5-FE2431D2DDE4Q30455973-4D50D99B-1C03-4453-8CBB-BF46A83C400CQ33582165-C1E99478-AA85-42FB-8F1F-EAAD82CE072FQ33618665-4CB736E9-9570-49F3-9A98-5D52AB710E34Q34531474-B4068E7C-397F-46C1-8F0B-8FA825AAB5AFQ35127787-94A900AB-D070-4D9C-B675-925BC9760961Q36228145-F761E672-1E5E-4C34-9576-7BE1229505A0Q37211153-B7186C2E-EECD-432B-971C-5FD2847455FEQ37408915-E3F046F8-BD6B-47A2-AC13-43DEAAF42863Q37454444-A7866FE6-6106-44E8-9390-5069BFA6BBC1Q37544401-ECB1FE17-E748-4B2F-BBF8-34E69833AD3DQ38062022-54B87296-B695-4ABD-9857-B371E6D6D5EAQ38114062-9D64CF8E-64AD-4D20-AD1D-32D7122A1780Q38166329-4CF83BC7-AF5F-4B47-B034-423304D6A221Q38219239-FE7F69D0-B685-4F51-8334-9A0E665D47B8Q38845317-FB811359-9F34-4D72-9459-4C2365A5173CQ38878259-C03B19F1-701A-45CF-BE94-C8A2ABE36DE0Q38969661-365C1DBB-80F7-4E47-B789-D03C97D69341Q41155758-D76280DC-95BC-4768-9C65-8EE31D7A7031Q58759036-7BD26119-3DE7-41F2-8F0D-6D61A31CBC1B
P2860
Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Targeted systemic therapies fo ...... s, challenges and implications
@ast
Targeted systemic therapies fo ...... s, challenges and implications
@en
type
label
Targeted systemic therapies fo ...... s, challenges and implications
@ast
Targeted systemic therapies fo ...... s, challenges and implications
@en
prefLabel
Targeted systemic therapies fo ...... s, challenges and implications
@ast
Targeted systemic therapies fo ...... s, challenges and implications
@en
P2860
P356
P1476
Targeted systemic therapies fo ...... s, challenges and implications
@en
P2093
Catherine Frenette
P2860
P304
P356
10.3748/WJG.V18.I6.498
P407
P50
P577
2012-02-01T00:00:00Z